SG 9701963-2
Dump copy

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C07K 14/78, 7/56, A61K 38/39, 38/12

A1

(11) International Publication Number: WO 96/20216

(43) International Publication Date: 4 July 1996 (04.07.96)

(21) International Application Number: PCT/GB95/02992

(22) International Filing Date: 21 December 1995 (21.12.95)

(30) Priority Data:

9426254.0	24 December 1994 (24.12.94)	GB
9505905.1	23 March 1995 (23.03.95)	GB
9513904.4	7 July 1995 (07.07.95)	GB

(81) Designated States: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

SG 9701963-2


(71) Applicant *(for all designated States except US)*: ZENECA LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB).

(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: DUTTA, Anand, Swaroop [GB/GB]; Zeneca Pharmaceuticals, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(74) Agent: DENERLEY, Paul, Millington; Zeneca Pharmaceuticals, Intellectual Property Dept., Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(54) Title: FIBRONECTIN ADHESION INHIBITORS

(57) Abstract



(1)

Cyclic peptides of formula (1) wherein: AA1 is an L or D amino acid selected form Ile and Leu or amino acid analogue thereof; AA2 is an L amino acid selected from Leu or amino acid analogue thereof; AA3 is an L amino acid selected from Asp or amino acid analogue thereof containing a carboxyl group in its side chain; AA4 is an L amino acid selected from Val or amino acid analogue thereof and; LINKER represents a linking moiety for linking N terminus of AA1 to C terminus of AA4 to form a cyclic peptide containing a heterocyclic ring having 17 to 30 members. The cyclic peptides inhibit the interaction of vascular cell adhesion molecule-1 and fibronectin with integrin very late antigen 4 and have therapeutic applications such as in rheumatoid arthritis or multiple sclerosis.